Healthcare
Regenexbio – SUCCESS PAGE – July 24, 2025
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
BrainScope has a pipeline that spans stroke, Alzheimer’s, concussion, and beyond, and is uniquely positioned in a $21B+ global market
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
BrainScope has a pipeline that spans stroke, Alzheimer’s, concussion, and beyond, and is uniquely positioned in a $21B+ global market
Aurenar has developed a non-invasive device that boosts the body’s natural control of inflammation, improving ICU outcomes and lowering costs.
Aurenar has developed a non-invasive device that boosts the body’s natural control of inflammation, improving ICU outcomes and lowering costs.
A biopharmaceutical company developing the first hormone-free, topical treatment for Vulvovaginal Atrophy (VVA)
A biopharmaceutical company developing the first hormone-free, topical treatment for Vulvovaginal Atrophy (VVA)
Serina Therapeutics (NYSE: SER) is pioneering drug optimization technologies to redefine the standard of care in advanced Parkinson’s and other diseases
Serina Therapeutics (NYSE: SER) is pioneering drug optimization technologies to redefine the standard of care in advanced Parkinson’s and other diseases
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.